Introduction:
Efficacy and safety of routine prophylaxis vs on-demand treatment with Bayer’s sucrose-formulated recombinant factor VIII (rFVIII-FS) in patients with severe hemophilia A were evaluated in the randomized, controlled…
Our Commitment to PrivacyThe National Bleeding Disorders Foundation (NBDF) respects the privacy of every individual who visits these NBDF websites: https://bleeding.org, https://hemaware.org, https://events.bleeding.org, https://stepsforliving…
The National Bleeding Disorders Foundation (the “Charity”), a not‐for‐profit organization organized in the State of New York encourages the solicitation and acceptance of gifts to further and fulfill its mission of finding better treatments and…
*/
PURPOSE
The National Bleeding Disorders Foundation, hereinafter referred to as “NBDF” is committed to lawful and ethical behavior in all of its activities and requires directors, volunteers, employees to act in accordance with all applicable…
NBDF General Conflict of Interest Discslosure
NBDF Policy on Financial Conflicts of Interest (FCOI) in Federally Sponsored Research Activities
The organization rebranded to NBDF in August 2023. Previously, the organization was known as the…
Asociación Puertorriqueña de Hemofilia y Condiciones de Sangrado
Introduction:
BAY 81-8973 is Bayer’s new full-length recombinant factor VIII (FVIII) product for the treatment of hemophilia A, with no human- or animal-derived raw materials added to the cell culture, purification, or…